CNGH0010 Specific Polynucleotides, Polypeptides, Antibodies, Compositions, Methods and Uses

Abstract

Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, psoriasis, rheumatoid arthritis, emphysema, asthma, diabetes, autoimmune thyroiditis, inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, different types of dermatitis including allergic dermatitis, contact dermatitis, actinic keratosis, wound healing, scar formation, various renal diseases, various respiratory diseases, various diseases of reproductive organs, such as endometriosis, melanoma, squamous cell carcinoma, ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer, renal cell carcinoma, Grave's diseases and other inflammatory and hyperproliferative diseases.

1 . An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, and 40 or an exact complement of said nucleotide sequence. 
     
     
         2 . An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41. 
     
     
         3 . An isolated nucleic acid molecule encoding a naturally occurring allelic variant of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41. 
     
     
         4 . An isolated nucleic acid molecule comprising a nucleotide sequence having at least 90% identity to any one of SEQ ID NOS:2, 4, 6, 8, 10, and 40 or an exact complement of said nucleotide sequence. 
     
     
         5 . An isolated nucleic acid molecule comprising a nucleotide sequence having at least 70% identity to any one of SEQ ID NOS :2, 4, 6, 8, 10, and 40 or an exact complement of said nucleotide sequence. 
     
     
         6 . An isolated nucleic acid molecule comprising a nucleotide sequence of at least 45 nucleotide residues having at least 90% identity to a portion of any one of SEQ ID NOS:2, 4, 6, 8, 10, and 40 or an exact complement of said nucleotide sequence. 
     
     
         7 . An isolated nucleic acid molecule encoding a fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41 wherein the fragment has an amino acid sequence comprising at least 15 consecutive amino acid residues of an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41. 
     
     
         8 . The nucleic acid molecule of  claim 1 , wherein the nucleotide sequence further comprises a portion encoding a heterologous polypeptide. 
     
     
         9 . The nucleic acid molecule according to  claim 1 , further comprising vector nucleic acid residues. 
     
     
         10 . A vector comprising the nucleic acid molecule of  claim 9   
     
     
         11 . A host cell containing the nucleic acid molecule of  claim 9 . 
     
     
         12 . The host cell of  claim 11 , wherein the host cell is of mammalian, bacterial, yeast, or insect origin. 
     
     
         13 . A kit comprising (i) a compound hybridizing with a nucleic acid molecule having a nucleotide sequence with at least 95% identity to any of SEQ ID NOS:1, 2, 4, 6, 8, and 10 in 6×SSC at about 45° C. followed by washing in 0.2×SSC, 0.1% SDS at about 65° C., and (ii) instructions for use. 
     
     
         14 . An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41. 
     
     
         15 . An isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41. 
     
     
         16 . An isolated polypeptide comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41. 
     
     
         17 . An isolated polypeptide comprising at least 15 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 5, 7, 9, 11, and 41. 
     
     
         18 . A fusion polypeptide comprising the polypeptide of  claim 14  operably linked to a heterologous polypeptide. 
     
     
         19 . The fusion polypeptide of  claim 18  wherein the heterologous polypeptide is a member of the immunoglobulin protein family or a fragment of said member. 
     
     
         20 . The polypeptide according to  claim 14 , wherein said polypeptide has at least one activity of a CNGH0010 polypeptide. 
     
     
         21 . The polypeptide of  claim 20 , wherein the polypeptide is glycosylated. 
     
     
         22 . The polypeptide of  claim 21 , wherein the polypeptide is O-linked glycosylated. 
     
     
         23 . An antibody comprising a monoclonal or polyclonal antibody, fusion protein, or fragment thereof, specifically binding to a polypeptide according to  claim 14 . 
     
     
         24 . An isolated nucleic acid molecule encoding the antibody of  claim 23 . 
     
     
         25 . A method for producing at least one CNGH0010 antibody, comprising translating the nucleic acid molecule of  claim 24 , under conditions in vitro, in vivo or in situ, wherein the CNGH0010 antibody is expressed in detectable or recoverable amounts. 
     
     
         26 . An antibody produced by the method of  claim 25 . 
     
     
         27 . A vector comprising the isolated nucleic acid molecule of  claim 24 . 
     
     
         28 . A host cell comprising the isolated nucleic acid molecule of  claim 24 , wherein the host cell is prokaryotic or eukaryotic. 
     
     
         29 . The host cell of  claim 28 , wherein the host cell is one or more selected from COS-1, COS-7, HEK293, BHK21, CRO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, and lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
     
     
         30 . A method for producing at least one CNGH0010 polypeptide, comprising translating the nucleic acid molecule of  claim 1 , under conditions in vitro, in vivo or in situ, wherein the CNGH0010 polypeptide is expressed in detectable or recoverable amounts. 
     
     
         31 . A polypeptide produced by the method of  claim 30 . 
     
     
         32 . A method for generating antibodies for a polypeptide, comprising immunizing or screening recombinant antibodies with a polypeptide according to  claim 14 . 
     
     
         33 . A composition comprising the nucleic acid molecule of  claim 1 , a polypeptide encoded by the nucleic acid, or an antibody to the polypeptide. 
     
     
         34 . A composition comprising an agonist or antagonist of one or more of the nucleic acid molecule of  claim 1 , a polypeptide encoded by the nucleic acid molecule, or an antibody to the polypeptide. 
     
     
         35 . The composition of  claim 34 , wherein said composition further comprises a pharmaceutically acceptable carrier or diluent. 
     
     
         36 . The composition of  claim 34 , administered in combination with a composition comprising one or more compound, composition or polypeptide selected from the group consisting of a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional supplement, a cytokine, and a cytokine antagonist. 
     
     
         37 . The composition of  claim 34 , in a form of one or more selected from the group consisting of a liquid or gas solution, mixture, suspension, emulsion or colloid, a lyophilized preparation, and a powder. 
     
     
         38 . A method for diagnosing a CNGH0010-related condition in a cell, tissue, organ or animal, comprising contacting or administering a composition comprising means for detection of one or more of the nucleic acid molecule of  claim 1 , a polypeptide encoded by the nucleic acid molecule, or an antibody to the polypeptide, in said cell, tissue, organ or animal. 
     
     
         39 . A method for treating a CNGH0010-related condition in a cell, tissue, organ or animal, comprising contacting or administering to a patient a composition comprising an effective amount of one or more of the composition of  claim 33  or an agonist or antagonist to the composition, with or to said cell, tissue, organ or animal. 
     
     
         40 . A method according to  claim 39  wherein said effective amount is about 0.001-50 mg of the antibody; about 0.000001-500 mg of the polypeptide; or about 0.0001-100 μg of the nucleic acid molecule per kilogram of said cells, tissue, organ or animal. 
     
     
         41 . A method according to  claim 39 , wherein said contact or administration is by one or more modes selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
     
     
         42 . A method according to  claim 41 , further comprising administering, prior, concurrently or after said contacting or administering step, at least one composition comprising an effective amount of one or more compound or polypeptide selected from the group consisting of a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional supplement, a cytokine, and a cytokine antagonist. 
     
     
         43 . A method for treating a CNGH0010-related condition in a cell, tissue, organ or animal, comprising contacting or administering to a patient a composition comprising an effective amount of one or more modulator of CNGH0010 nucleic acid molecule or CNGH0010 polypeptide levels or a modulator of CNGH0010 activity in said cell, tissue, organ or animal. 
     
     
         44 . A method for treating an epithelial-related condition in a cell, tissue, organ or animal, comprising contacting or administering to a patient a composition comprising an effective amount of the composition of  claim 33  or an agonist or antagonist to the composition, with or to said cell, tissue, organ or animal. 
     
     
         45 . A method for treating an epithelial-related condition in a cell, tissue, organ or animal, comprising contacting or administering to a patient a composition comprising an effective amount of at least one modulator of CNGH0010 nucleic acid molecule or CNGH0010 polypeptide levels or a modulator of CNGH0010 activity in said cell, tissue, organ or animal. 
     
     
         46 . A device comprising one or more of the nucleic acid molecule of  claim 1 , a polypeptide encoded by the nucleic acid molecule, and an antibody, agonist or antagonist to the polypeptide, wherein said device is suitable for contacting or administering one or more of said polypeptide, antibody, agonist, antagonist, or nucleic acid molecule, by one or more modes selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
     
     
         47 . An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising one or more of the nucleic acid molecule of  claim 1 , a polypeptide encoded by the nucleic acid molecule, and an antibody, agonist or antagonist to the polypeptide. 
     
     
         48 . The article of manufacture of  claim 47 , wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system. 
     
     
         49 . A method for producing one or more of the nucleic acid molecule of  claim 1 , a polypeptide encoded by the nucleic acid molecule, and an antibody, agonist or antagonist to the polypeptide, comprising providing one or more vector, host cell, transgenic animal, transgenic plant, or plant cell capable of transcribing said nucleic acid and/or expressing in detectable or recoverable amounts said polypeptide or antibody. 
     
     
         50 . A polypeptide, antibody, agonist, antagonist or nucleic acid molecule, produced by the method of  claim 49 . 
     
     
         51 . A method for detecting the presence or absence of the nucleic acid molecule according to  claim 1  or a polypeptide encoded by the nucleic acid molecule in a biological sample, comprising obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting said polypeptide wherein the presence of the polypeptide or nucleic acid molecule is detected in the biological sample. 
     
     
         52 . An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 10 1-526 (Exon 1), 786-986 (Exon 2), 1099-1155 (Exon 3), 1763-1813 (Exon 4), 1983-2165 (Exon 5), 3324-3392 (Exon 8), 7590-7637 (Exon 13), 7811-7858 (Exon 14), 10690-10746 (Exon 16), 11393-11440 (Exon 17), 12996-13043 (Exon 19), 13547-13618 (Exon 21), 14679-14702 (Exon 22), 14813-14860 (Exon 23), and 16038-16356 (Exon 25) of SEQ ID NO:1 and, optionally, one or more from the group consisting of nucleotides 2936-2980 (Exon 6), 3615-3665 (Exon 9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), 7391-7450 (Exon 12), 13157-13198 (Exon20), and 15895-15929 (Exon24) of SEQ ID NO:1, or an exact complement of said nucleotide sequence. 
     
     
         53 . An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 10 1-526 (Exon 1), 786-986 (Exon 2), 1099-1155 (Exon 3), 1763-1813 (Exon 4), 1983-2165 (Exon 5), 3324-3392 (Exon 8), 7590-7637 (Exon 13), 7811-7858 (Exon 14), and 10129-10155 (Exon 15) of SEQ ID NO:1 and, optionally, one or more from the group consisting of nucleotides 3615-3665 (Exon 9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), and 7391-7450 (Exon 12) of SEQ ID NO:1, or an exact complement of said nucleotide sequence. 
     
     
         54 . An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 3149-3205 (Exon 7), 3324-3392 (Exon 8), 7590-7637 (Exon 13), 7811-7858 (Exon 14), 10690-10746 (Exon 16), 11393-11440 (Exon 17), 12996-13043 (Exon 19), 13547-13618 (Exon21), 14679-14702 (Exon 22), 14813-14860 (Exon 23), and 16038-16356 (Exon 25) of SEQ ID NO: 1 and, optionally, one or more from the group consisting of nucleotides 3615-3665 (Exon 9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), 7391-7450 (Exon 12), 13157-13198 (Exon20), and 15895-15929 (Exon24) of SEQ ID NO:1, or an exact complement of said nucleotide sequence. 
     
     
         55 . An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 3149-3205 (Exon 7), 3324-3392 (Exon 8), 7590-7637 (Exon 13), 7811-7858 (Exon 14), and 10129-10155 (Exon 15) of SEQ ID NO: 1 and, optionally, one or more from the group consisting of nucleotides 3615-3665 (Exon9), 5336-5371 (Exon 10), 6065-6118 (Exon 11), and 7391-7450 (Exon 12) of SEQ ID NO:1, or an exact complement of said nucleotide sequence. 
     
     
         56 . An isolated nucleic acid molecule comprising a nucleotide sequence of nucleotides 101-526 (Exon 1), 786-986 (Exon 2), 1099-1155 (Exon 3), 1763-1813 (Exon 4), 1983-2165 (Exon 5), 3324-3392 (Exon 8), 7391-7450 (Exon 12), and 7590-7637 (Exon 13) of SEQ ID NO:1, or an exact complement of said nucleotide sequence. 
     
     
         57 . An isolated nucleic acid molecule comprising a nucleotide sequence having at least 90% identity to any of the nucleotide sequences recited in  claim 52 , or an exact complement of said nucleotide sequence. 
     
     
         58 . An isolated nucleic acid molecule encoding a fragment of a polypeptide having an amino acid sequence encoded by any of the nucleotide sequences recited in  claim 52 , wherein the fragment has an amino acid sequence comprising at least 15 consecutive amino acid residues of an amino acid sequence encoded by any of the nucleotide sequences recited in  claim 52 . 
     
     
         59 . The nucleic acid molecule according to  claims 52 , wherein the nucleotide sequence further comprises a portion encoding a heterologous polypeptide. 
     
     
         60 . The nucleic acid molecule according to any of  claim 52 , further comprising vector nucleic acid residues. 
     
     
         61 . A vector comprising the nucleic acid molecule of  claim 60 . 
     
     
         62 . A host cell containing the nucleic acid molecule of  claim 60 . 
     
     
         63 . The host cell of  claim 62 , wherein the host cell is of mammalian, bacterial, yeast, or insect origin. 
     
     
         64 . A kit comprising (i) a compound hybridizing with a nucleic acid molecule having a nucleotide sequence with at least 95% identity to the nucleotide sequences according to  claim 52  in 6×SSC at about 45° C. followed by washing in 0.2×SSC, 0.1% SDS at about 65° C., and (ii) instructions for use. 
     
     
         65 . An isolated polypeptide encoded by any of the nucleotide sequences according to  claim 52 . 
     
     
         66 . An isolated polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence encoded by any of the nucleotide sequences according to  claim 52 . 
     
     
         67 . An isolated polypeptide comprising at least  15  contiguous amino acids of the amino acid sequence encoded by any of the nucleotide sequences according to  claim 52 . 
     
     
         68 . A fusion polypeptide comprising the polypeptide of  claim 65  operably linked to a heterologous polypeptide. 
     
     
         69 . The fusion polypeptide of  claim 68  wherein the heterologous polypeptide is a member of the immunoglobulin protein family or a fragment of said member. 
     
     
         70 . The polypeptide according to  claim 65 , wherein said polypeptide has at least one activity of a CNGH0010 polypeptide. 
     
     
         71 . An antibody comprising a monoclonal or polyclonal antibody, fusion protein, or fragment thereof, specifically binding to the polypeptide of  claim 65 . 
     
     
         72 . An isolated nucleic acid molecule encoding the antibody of  claim 71 . 
     
     
         73 . A method for producing an antibody, comprising translating the nucleic acid molecule of  claim 72 , under conditions in vitro, in vivo or in situ, wherein the antibody is expressed in detectable or recoverable amounts. 
     
     
         74 . An antibody produced by the method of  claim 73 . 
     
     
         75 . A vector comprising the isolated nucleic acid molecule of  claim 72 . 
     
     
         76 . A host cell comprising the isolated nucleic acid molecule of  claim 72 , wherein the host cell is prokaryotic or eukaryotic. 
     
     
         77 . The host cell of  claim 76 , wherein the host cell is one or more selected from COS-1, COS-7, HEK293, BHK21, CRO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, and lymphoma cells, or any derivative, immortalized or transformed cell thereof. 
     
     
         78 . A method for producing a CNGH0010 polypeptide, comprising translating the nucleic acid molecule according to  claim 52 , under conditions in vitro, in vivo or in situ, wherein the CNGH0010 polypeptide is expressed in detectable or recoverable amounts. 
     
     
         79 . A polypeptide produced by the method of  claim 78 . 
     
     
         80 . A method for generating antibodies for a polypeptide, comprising immunizing or screening recombinant antibodies with a polypeptide according to  claim 65 . 
     
     
         81 . A composition comprising one or more of the nucleic acid molecule according to  claim 52 , a polypeptide encoded by the nucleic acid molecule, and an antibody to the polypeptide. 
     
     
         82 . A composition comprising an agonist or antagonist of one or more of the nucleic acid molecule according to  claim 52 , a polypeptide encoded by the nucleic acid molecule, and an antibody to the polypeptide. 
     
     
         83 . The composition of  claim 82 , wherein said composition further comprises at least one pharmaceutically acceptable carrier or diluent. 
     
     
         84 . An isolated nucleic acid molecule comprising a truncated CNGH0010 nucleotide sequence containing one or more from the group consisting of nucleotides 1983-2076 (Exon 5a), 2117-2165 (Exon 5b), 3168-3197 (Exon 7a), and 3189-3393 (Exon 8a) of SEQ ID NO:1. 
     
     
         85 . Any invention described herein.